Hepatitis B Virus – Epidemiology – Epidemiology Dashboard
Clarivate Epidemiology’s coverage of hepatitis B virus (HBV) infection comprises epidemiological estimates of key patient populations in 45 countries. We report the total prevalence of HBV in each country, as well as annualized case counts projected to the national population.
The patient populations are forecast over a period of 10 years for all countries covered in this report.
All forecast data are available on the Clarivate Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate Epidemiology’s HBV infection forecast will answer the following questions:
How will changes in HBV coverage impact the prevalence of HBV infection?
Of all people diagnosed with HBV infection, how many in each of the major mature pharmaceutical markets are drug-treated?
How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of HBV infection over the forecast period?
Hepatitis B Virus - Epidemiology - Epidemiology Dashboard
Introduction
HBVu00a0Infection Epidemiology Dashboard
T.J. Arndt, M.P.H., C.P.H.
Thomas J. Arndt, M.P.H., C.P.H., is a senior epidemiologist at Clarivate. He earned his master’s degree in public health at the University of Florida, where he conducted an internship developing a clinical model for noninvasively screening for nonalcoholic steatohepatitis (NASH). He also holds a B.S. in microbiology and cell science and a B.A. in Spanish, both from the University of Florida. While studying at the University of Florida, Mr. Arndt worked in two physiology-based research labs focusing on maternal and fetal stresses during pregnancy and parturition.
